Topics covered in this edition of the newsletter include:
Domperidone-containing medicines: risk of cardiac adverse reactions-restricted indication, new contraindications and reduced dose and duration of use
Recommendation to restrict the combined use of medicines affecting the renin-angiotensin (RAS) system
Reminder regarding the risk of serious hypersensitivity reactions with Rienso (ferumoxytol)
Direct Healthcare Professional Communications published on the IMB website since the last Drug Safety Newsletter